Our study aims to determine the clinical significance of human telomerase reverse transcriptase (hTERT), S-phase kinase-associated protein 2 (Skp2) and thyroid transcription factor-1 (TTF-1) mRNA expressions in peripheral blood (PB) of patients with non-small cell lung cancer (NSCLC). Real-time polymerase chain reaction was used to investigate the gene expressions of hTERT, Skp2, TTF-1 as in the PB of 60 patients with NSCLC and 20 benign lung diseases.
Non-small cell lung cancer
Echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangements and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) have been intensively studied. The objective of this study was to determine the clinicopathological characteristics in genotype-specific subsets of patients with NSCLC to help ensure the optimal identification of patients whose tumors harbor these two driver mutations.
The expression of CK19, LUNX, and KS1/4 mRNA biomarkers was detected in the peripheral blood of non-small cell lung cancer (NSCLC) patients to investigate the feasibility of indicating lung cancer micrometastases. Micrometastases were identified in the peripheral blood of 32 NSCLC patients, 15 benign pulmonary disease (BPD) patients, and 10 healthy volunteers by reverse transcriptase-polymerase chain reaction.
The specific correlation between CXCR4 expression and survival in non-small cell lung cancer (NSCLC) has been investigated independently; however, these have yielded inconsistent results. Therefore, we examined the exact relationship between CXCR4 expression and NSCLC in this meta-analysis. The bibliographic databases in English and Chinese were carefully searched and data regarding the prognostic value of CXCR4 and its association with pathological parameters of NSCLC were collected. Pooled odds ratios (OR) with 95% confidence interval (CI) were applied.
Many studies have shown that genetic factors, environmental factors, and bad living habits, especially smoking, are risk factors for lung cancer. However, not all smokers develop lung cancer, which may be related to different genetic backgrounds. Currently, most research has investigated the GSTM1, XRCC1, XRCC3, CYP2D6, and C188T genes. Little research has been done on the cytochrome P450 (CYP) 1A1 gene, and results have varied.
We aimed to analyze the changes of serum vascular endothelial growth factor (VEGF) before and after microwave ablation (MWA) in patients with stage IIIB-IV non-small cell lung cancer (NSCLC), and to observe the effects of MWA combined with chemotherapy on short-term therapeutic efficacy and long-term survival. Concentrations of serum VEGF in 20 healthy subjects were considered as controls. Changes of serum VEGF were detected by ELISA before and after MWA (1 and 7 days after treatment).
We investigated the methylation state of the epidermal growth factor receptor (EGFR) gene promoter in non-small cell lung cancer (NSCLC) and analyzed its effect on tumor biology. We enrolled 120 patients with NSCLC who had been confirmed by pathologic diagnosis and had been operated on. The methylation states of the EGFR gene promoter were detected and analyzed and a prognosis was given. NSCLC cell lines and nude mice were used to study the treatment reactivity of gefitinib (an EGFR inhibitor) with or without 5-aza-2'-deoxycytidine (5-aza-CdR) intervention.
We explored the expression and clinical significance of circulating tumor cells (CTCs) in patients with advanced non-small cell lung cancer (NSCLC). Sixty-six patients with advanced NSCLC at the Oncology Department of Jinzhou Hospital were selected as an observation group between February and December 2013. Healthy volunteers and 20 benign lung disease patients were taken as a control group. Peripheral blood CTCs in the observation and control groups were detected using the CellSearch®.
To compare the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) therapy combined with concurrent radiochemotherapy on stage IIIB non-small cell lung cancer. Sixty-three patients with stage IIIB non-small cell lung cancer were randomly divided into the study and control groups. The study group, comprising 30 patients, was treated with DC-CIK combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy. The control group including 33 patients was only treated with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy.